Medical University Innsbruck, Department of Psychiatry, Innsbruck, Austria.
Pharmacopsychiatry. 2010 Mar;43(2):41-4. doi: 10.1055/s-0030-1249071. Epub 2010 Feb 19.
Clozapine is known to induce neutropenia as well as agranulocytosis. Some cases of olanzapine- and risperidone-induced neutropenia and agranulocytosis have also been reported. We prospectively investigated schizophrenia patients treated with second generation antipsychotics with respect to alterations of white blood cell counts.
In an analysis of our drug monitoring program, we studied white blood cell counts in 104 patients receiving different second generation antipsychotics other than clozapine for at least six months and compared them with those of 28 patients receiving clozapine.
We found neutropenia (neutrophils <2 000/microL) in the mixed group in 17.6% and in 11.8% of patients treated with clozapine during the first 6 months. There was no statistically significant difference between those groups with respect to the risk to develop neutropenia during the investigation period. There was no case of agranulocytosis. Neutropenia was transient in all patients. Eosinophilia occurred in some patients that developed neutropenia later on but had no significant predictive value.
氯氮平已知可引起中性粒细胞减少症和粒细胞缺乏症。也有报道奥氮平和利培酮引起的中性粒细胞减少症和粒细胞缺乏症的病例。我们前瞻性地研究了接受第二代抗精神病药物治疗的精神分裂症患者的白细胞计数变化。
在我们的药物监测计划的分析中，我们研究了 104 名接受除氯氮平以外的不同第二代抗精神病药物治疗至少 6 个月的患者的白细胞计数，并将其与 28 名接受氯氮平治疗的患者进行了比较。
我们发现混合组在治疗的前 6 个月中有 17.6%和 11.8%的患者出现中性粒细胞减少症（中性粒细胞<2000/μL）。在研究期间发生中性粒细胞减少症的风险方面，两组之间无统计学差异。没有粒细胞缺乏症的病例。所有患者的中性粒细胞减少症均为一过性。一些发生中性粒细胞减少症的患者出现了嗜酸性粒细胞增多，但无显著预测价值。
